4 news items
Palo Alto Networks Shares Drop After Q3 Results, In-Line Guidance: The Details
PANW
VXRT
20 May 24
billion from the same period last year.
“We are pleased with the enthusiastic response to platformization from our customers in Q3
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
VXRT
13 May 24
on the most vulnerable populations," Lo added. "Recent preclinical data suggests our COVID-19 XBB construct showed a more robust immunogenic response compared
Vaxart Announces Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers; Long-Term Goal Is To Provide Protection To Infants Through Passive Antibody Transfer
VXRT
30 Apr 24
for each arm) or placebo (N=16). The primary endpoint results were:Serum VP1-specific IgA rose an average of 5.6 fold in response to GI.1
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
VXRT
14 Mar 24
. In February 2024, Vaxart published preclinical non-human primate (NHP) data showing strong cross-reactive immune responses, thus demonstrating
- Prev
- 1
- Next